Exhibit 99.1 McKESSON CORPORATION REPORTS FISCAL 2025 THIRD QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE IRVING, Texas, February 5, 2025 - McKesson Corporation (NYSE:MCK) today announced results for the third quarter ended December 31, 2024. Third Quarter Highlights: Fiscal 2025 Outlook: "McKesson reported strong third quarter operational results with broad-based Revenue growth of 18% and Adjusted Operating Profit growth of 16%. Our performance reflects the strength and momentum across the ent ...

McKesson Corporation (MCK) recently announced that it has signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a premier provider of general ophthalmology and retina management services, from Quad-C.McKesson is likely to purchase an 80% stake in  PRISM Vision Holdings for approximately $850 million, while physicians will continue to retain a 20% interest.Likely Trend of MCK Stock Following the NewsFollowing the announcement, shares of the company clos ...

McKesson Corporation (MCK) is scheduled to report third-quarter fiscal 2025 results on Feb. 5, after market close.The company delivered an earnings surprise of 2.61% in the last reported quarter. Its earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 4.99%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.McKesson’s revenue growth has been driven largely by the rapid adoption of GLP-1 weight loss drugs and sustained demand ...

Wall Street analysts forecast that McKesson (MCK) will report quarterly earnings of $8.11 per share in its upcoming release, pointing to a year-over-year increase of 4.8%. It is anticipated that revenues will amount to $95.46 billion, exhibiting an increase of 18% compared to the year-ago quarter.The current level reflects an upward revision of 1.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their i ...

Stock Performance - McKesson's stock ended at $602 95, marking a -0 24% decline from the previous day's close [1] - Over the past month, McKesson's shares gained 5 9%, outperforming the Medical sector's 3 83% gain and the S&P 500's 0 81% gain [1] Earnings and Revenue Projections - McKesson is scheduled to release its earnings on February 5, 2025, with projected EPS of $8 19, a 5 81% increase from the same quarter last year [2] - Revenue for the upcoming quarter is projected at $95 46 billion, up 18% year-over-year [2] - For the entire year, earnings are forecasted at $32 72 per share, a 19 24% increase, and revenue at $358 91 billion, a 16 17% increase compared to the previous year [3] Analyst Estimates and Valuation - Recent adjustments to analyst estimates reflect short-term business dynamics, with positive changes indicating a favorable outlook on the company's profitability [4] - McKesson currently has a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate decreasing by 0 02% over the past month [6] - The company's Forward P/E ratio is 18 47, in line with the industry average [7] - McKesson's PEG ratio is 1 31, lower than the Medical - Dental Supplies industry average of 2 1 [8] Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 137, placing it in the bottom 46% of over 250 industries [8] - The Zacks Industry Rank shows that the top 50% of industries outperform the bottom half by a factor of 2 to 1 [9]

Company Performance - McKesson's stock closed at $586.08, reflecting a -1.1% change from the previous day, underperforming the S&P 500's gain of 0.88% [1] - Over the past month, McKesson's stock has increased by 2.74%, while the Medical sector has seen a loss of 0.32% and the S&P 500 has gained 1.17% [1] Upcoming Earnings - McKesson's earnings report is anticipated on February 5, 2025, with projected earnings per share (EPS) of $8.28, indicating a 6.98% increase from the same quarter last year [2] - Revenue is expected to reach $95.46 billion, reflecting an 18% growth compared to the same quarter of the previous year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $32.73 per share and revenue at $358.91 billion, representing increases of +19.28% and +16.17% respectively from the prior year [3] Analyst Estimates - Recent changes to analyst estimates for McKesson are significant as they reflect the evolving business trends, with positive revisions indicating analysts' confidence in the company's performance [4] - The Zacks Rank system, which evaluates estimate changes, currently ranks McKesson at 3 (Hold) [6] Valuation Metrics - McKesson has a Forward P/E ratio of 18.11, which aligns with its industry's Forward P/E of 18.11, indicating no significant deviation [7] - The company holds a PEG ratio of 1.28, compared to the average PEG ratio of 2 for the Medical - Dental Supplies industry [8] Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 150, placing it in the bottom 41% of over 250 industries [9]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on McKesson (MCK), and highlights the potential misalignment of interests between brokerage firms and retail investors [1][4]. Group 1: Brokerage Recommendations - McKesson has an average brokerage recommendation (ABR) of 1.38, indicating a consensus between Strong Buy and Buy, based on 16 brokerage firms [2]. - Out of the 16 recommendations, 13 are Strong Buy, accounting for 81.3% of all recommendations [2]. - Despite the positive ABR, relying solely on this information for investment decisions may not be advisable, as studies suggest brokerage recommendations often fail to guide investors effectively [4]. Group 2: Analyst Bias and Zacks Rank - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, with a ratio of five "Strong Buy" recommendations for every "Strong Sell" [5][9]. - The Zacks Rank, which is based on earnings estimate revisions, is presented as a more reliable indicator of near-term stock performance compared to ABR [7][10]. - The Zacks Rank is timely and reflects the latest earnings estimates, while ABR may not always be up-to-date [11]. Group 3: Current Earnings Estimates for McKesson - The Zacks Consensus Estimate for McKesson's earnings for the current year remains unchanged at $32.73, suggesting stable analyst views on the company's earnings prospects [12]. - The recent change in consensus estimates, along with other factors, has resulted in a Zacks Rank of 3 (Hold) for McKesson, indicating a cautious approach despite the positive ABR [13].

Core Insights - McKesson (MCK) has started 2025 positively, with a 4% stock increase in January, driven by optimism regarding its performance and strategic focus on oncology and biopharma services [1][9] - The company reported strong second-quarter fiscal 2025 results, with U.S. Pharmaceutical segment revenues soaring 23% year over year to $85.7 billion, largely due to the growth of GLP-1 medications [10] - McKesson's strategic initiatives, including investments in technology and divestitures, are expected to enhance operational efficiency and focus on high-margin areas [2][17] Financial Performance - The U.S. Pharmaceutical segment's adjusted operating profit increased 11% to $902 million, supported by rising prescription volumes and the expansion of oncology services [10] - The International segment reported revenues of $3.7 billion, up 7% year over year, driven by higher pharmaceutical distribution volumes in Canada [11] - The Medical-Surgical Solutions segment grew 4% to $2.9 billion, with increased specialty pharmaceutical volumes partially offsetting challenges [12] - Prescription Technology Solutions (RxTS) revenues grew 11% to $1.3 billion, with automated prior authorizations saving patients over $2 billion in the second quarter [13] Strategic Focus - McKesson's focus on oncology and biopharma services is a major growth driver, with the U.S. Oncology Network expanding to over 3,300 providers [18] - The company is leveraging its scale and operational efficiency to enhance medication access and affordability through RxTS [17] - Strategic divestitures, including the sale of Rexall and Well.ca, are aimed at streamlining operations and reallocating resources to high-margin segments [2][18] Market Position - McKesson's stock is trading at a forward P/E of 16.5X, lower than the Medical Dental Supplies industry's 17.53X, indicating a favorable valuation [17] - The Medical-Dental Supplies industry has outperformed the broader medical sector and the S&P 500 Index, suggesting rising growth potential [4] Challenges - McKesson faces regulatory uncertainties, inflationary pressures, and potential supply-chain disruptions, which could impact margins and market share [3] - The Medical-Surgical Solutions segment reported a 4% decline in adjusted operating profit due to reduced primary care demand as market conditions normalized post-COVID-19 [21] - Rising operational costs in the U.S. Pharmaceutical segment have partially offset gains from other areas, impacting overall performance [22][23]

Company Performance - McKesson's stock closed at $585.08, with a daily increase of +0.57%, outperforming the S&P 500's gain of 0.16% [1] - Over the last month, McKesson's shares increased by 0.95%, while the Medical sector experienced a loss of 5.3% and the S&P 500 lost 2.2% [1] Upcoming Earnings - McKesson is set to disclose its earnings on February 5, 2025, with an expected EPS of $8.28, reflecting a 6.98% increase from the same quarter last year [2] - The revenue forecast for the upcoming earnings report is $95.46 billion, indicating an 18% growth compared to the same quarter of the previous year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict earnings of $32.73 per share and revenue of $358.91 billion, representing increases of +19.28% and +16.17% respectively from the previous year [3] - Recent changes in analyst estimates suggest a positive outlook for McKesson's business performance and profit potential [3] Valuation Metrics - McKesson has a Forward P/E ratio of 17.78, which is lower than the industry average Forward P/E of 18.04, indicating a potential valuation discount [5] - The company also has a PEG ratio of 1.26, compared to the Medical - Dental Supplies industry's average PEG ratio of 1.94, suggesting favorable growth expectations relative to its valuation [6] Industry Context - The Medical - Dental Supplies industry, which includes McKesson, holds a Zacks Industry Rank of 61, placing it in the top 25% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the strength of the industry [7]

Group 1: Twilio (TWLO) - Twilio enables developers to build, scale, and operate real-time communications within software applications [1] - The company has a Zacks Rank of 1 (Strong Buy) [1] - The Zacks Consensus Estimate for its current year earnings has increased by 6.7% over the last 60 days [1] - Twilio has a PEG ratio of 0.69 compared to the industry average of 1.84 [2] - The company possesses a Growth Score of A [2] Group 2: McKesson (MCK) - McKesson is a healthcare services and information technology company that distributes branded and generic pharmaceutical drugs globally [2] - The company carries a Zacks Rank of 1 (Strong Buy) [2] - The Zacks Consensus Estimate for its current year earnings has increased by 2.3% over the last 60 days [2] - McKesson has a PEG ratio of 1.23 compared to the industry average of 3.62 [3] - The company possesses a Growth Score of A [3] Group 3: ZIM Integrated Shipping Services (ZIM) - ZIM is a global container liner shipping company providing container shipping and related services internationally [3] - The company has a Zacks Rank of 1 (Strong Buy) [3] - The Zacks Consensus Estimate for its current year earnings has increased by 36.1% over the last 60 days [3] - ZIM has a PEG ratio of 0.04 compared to the industry average of 0.48 [4] - The company possesses a Growth Score of B [4]